89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

89Bio thinks its Phase II FGF21 analog could prove best-in-class in NASH due to a longer half-life than Bristol’s pegbelfermin, and avoid the LDL-increasing effects seen with NGM’s FGF19 analog.

competition
89Bio cites multiple reasons why its FGF21 analog for NASH might be best in class

Recent entrants, including some big pharma players, threaten to make the fibroblast growth factor (FGF) analog class another crowded field of clinical development for non-alcoholic steatohepatitis, but 89bio Inc. thinks its mid-stage FGF21 analog could prove best in class with less frequent dosing than a Phase II FGF21 candidate at Bristol-Myers Squibb Co. and offer a better safety profile than NGM Biopharmaceuticals Inc.’s Phase IIb FGF19 analog.

Founded in Israel in May 2018 with the licensing of BIO89-100 (then called TEVA47948) from Teva, 89Bio now operates mainly...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.